Drugs / Apatinib Mesylas
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT04479527 | Apr 2021 → Aug 2023 | hepatocellular carcinoma | Peking University Cancer Hospital & Institute | Unknown | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Apatinib Mesylas | “Apatinib Mesylas is a small-molecule VEGFR tyrosine kinase inhibitor.” NCT04479527 ↗ |
| Action | Inhibit | “mainly treats malignant tumors by inhibiting VEGFR to play an anti-angiogenic effect.” NCT04479527 ↗ |
| Modality | Small molecule | “Apatinib Mesylas is a small-molecule VEGFR tyrosine kinase inhibitor.” NCT04479527 ↗ |
| Route | Oral | “Apatinib mesylate tablets, 250mg/ time, once a day.” NCT04479527 ↗ |